197 related articles for article (PubMed ID: 26612860)
1. FOXO factors and breast cancer: outfoxing endocrine resistance.
Bullock M
Endocr Relat Cancer; 2016 Feb; 23(2):R113-30. PubMed ID: 26612860
[TBL] [Abstract][Full Text] [Related]
2. FOXO family in regulating cancer and metabolism.
Ma J; Matkar S; He X; Hua X
Semin Cancer Biol; 2018 Jun; 50():32-41. PubMed ID: 29410116
[TBL] [Abstract][Full Text] [Related]
3. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
[TBL] [Abstract][Full Text] [Related]
4. Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
Giuliano M; Schifp R; Osborne CK; Trivedi MV
Breast; 2011 Oct; 20 Suppl 3():S42-9. PubMed ID: 22015292
[TBL] [Abstract][Full Text] [Related]
5. Endocrine therapy resistance: current status, possible mechanisms and overcoming strategies.
Chang J; Fan W
Anticancer Agents Med Chem; 2013 Mar; 13(3):464-75. PubMed ID: 22931419
[TBL] [Abstract][Full Text] [Related]
6. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
8. Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches.
Raheem F; Karikalan SA; Batalini F; El Masry A; Mina L
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003387
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.
Zilli M; Grassadonia A; Tinari N; Di Giacobbe A; Gildetti S; Giampietro J; Natoli C; Iacobelli S;
Biochim Biophys Acta; 2009 Jan; 1795(1):62-81. PubMed ID: 18804516
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.
García-Becerra R; Santos N; Díaz L; Camacho J
Int J Mol Sci; 2012 Dec; 14(1):108-45. PubMed ID: 23344024
[TBL] [Abstract][Full Text] [Related]
11. FOXO Signaling Pathways as Therapeutic Targets in Cancer.
Farhan M; Wang H; Gaur U; Little PJ; Xu J; Zheng W
Int J Biol Sci; 2017; 13(7):815-827. PubMed ID: 28808415
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
13. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
14. Treatment for the endocrine resistant breast cancer: Current options and future perspectives.
Liu CY; Wu CY; Petrossian K; Huang TT; Tseng LM; Chen S
J Steroid Biochem Mol Biol; 2017 Sep; 172():166-175. PubMed ID: 28684381
[TBL] [Abstract][Full Text] [Related]
15. Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer.
Glück S
Clin Breast Cancer; 2017 Apr; 17(2):79-90. PubMed ID: 27687476
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Massarweh S; Schiff R
Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
[TBL] [Abstract][Full Text] [Related]
17. New approaches to reverse resistance to hormonal therapy in human breast cancer.
Weinberg OK; Marquez-Garban DC; Pietras RJ
Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
[TBL] [Abstract][Full Text] [Related]
18. Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine.
Matikas A; Foukakis T; Bergh J
Crit Rev Oncol Hematol; 2017 Jun; 114():91-101. PubMed ID: 28477750
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
[TBL] [Abstract][Full Text] [Related]
20. Emerging strategies to overcome resistance to endocrine therapy for breast cancer.
Ziauddin MF; Hua D; Tang SC
Cancer Metastasis Rev; 2014 Sep; 33(2-3):791-807. PubMed ID: 24944077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
